Radiotherapy of anal canal cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Radiotherapy of anal canal cancer

Published:2022-02 Issue:1-2 Volume:26 Page:279-285
ISSN:1278-3218
Container-title:Cancer/Radiothérapie
language:en
Short-container-title:Cancer/Radiothérapie

Author:

Peiffert D.,Huguet F.,Vendrely V.,Moureau-Zabotto L.,Rivin Del Campo E.,Créhange G.,Dietmann A.-S.,Moignier A.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference27 articles.

1. Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP);Moureau-Zabotto;Dig Liver Dis,2017

2. Temporal improvements in locoregional failure and survival in patients with anal cancer treated with chemoradiotherapy: treatment cohort study (1990–2014);Sekhar;Br J Cancer,2020

3. Anal canal carcinoma: early-stage tumors;Ortholan;Int J Radiat Oncol Biol Phys,2005

4. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up;Glynne-Jones;Eur J Surg Oncol,2014

5. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASE;Digestive and Liver Disease;2024-07

2. Radiation therapy of the primary tumour and/or metastases of digestive metastatic cancers;Cancer/Radiothérapie;2024-02

3. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE;Radiotherapy and Oncology;2023-06

4. Prise en charge des cancers du canal anal : mise au point et perspectives futures;Cancer/Radiothérapie;2022-10

5. Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma;Frontiers in Oncology;2022-08-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3